01 Industry overview
The market access pharmaceutical industry at a glance
Pharmaceutical market access is expanding as pricing, reimbursement and patient-support services respond to global medicine spending projected to exceed $2.6 trillion by 2030.
- $3.9B[87]
- Patient access support market, 2025
- 54.9%[88]
- Consulting share, 2025
- >$2.6T[20]
- Global medicine spending by 2030
- 22%[62]
- Estimated savings on 10 drugs, 2023
- Market size
- The global pharma hub and patient access support services market was estimated at $3.9 billion in 2025. A separate market-access-solutions estimate put the broader market at approximately $24.2 billion in 2025, with consulting services generating $13.26 billion.[87][88]
- Forecast & CAGR
- Global medicine spending is expected to exceed $2.6 trillion by 2030 and increase at an annual rate of 5%–8% through 2030. The patient access support services market report forecasts continued expansion through 2033, although its published search summary does not provide a comparable CAGR figure.[20][87]
- Market share & regions
- The United States remains a major market-access center because of its high medicine spending and complex payer structure. IQVIA identifies the United States, Europe and other developed markets alongside emerging markets as distinct regional drivers of global medicine-use growth, but the sources reviewed did not provide a consistent current regional market-share table for market-access services.[20][87]
- Segmentation
- Market-access services are commonly segmented into consulting services, software and IT solutions, pricing and revenue management, and health economics and outcomes research. Patient-access support is further described through reimbursement and affordability services, with delivery models and geography used as additional segmentation dimensions.[88][87]
- Key players & concentration
- The competitive landscape includes global life-sciences consultancies, healthcare agencies, analytics providers and patient-support platforms. The Access to Medicine Index evaluates 20 of the world’s largest research-based pharmaceutical companies, including Novartis, GSK, Sanofi, Pfizer and Johnson & Johnson, indicating a concentrated client base among large originator manufacturers rather than a single concentrated services market.[73]
- Pricing
- Pricing is increasingly shaped by negotiated net prices, rebates, reimbursement limits and outcomes evidence rather than list prices alone. For the first Medicare negotiation cycle, CMS estimated that negotiated prices for 10 selected drugs would have reduced 2023 spending by approximately $6 billion, or 22%, if they had applied that year.[62]
- Trends, drivers & challenges
- Key drivers include rising medicine utilization, specialty and high-cost therapies, evidence requirements, affordability pressure and the use of real-world data in reimbursement decisions. Major challenges are fragmented payer systems, increasing evidence demands, budget constraints and the need to balance access with incentives for pharmaceutical innovation.[20][62]
- Consumer behavior & competition
- Patients increasingly encounter access friction through prior authorization, affordability checks, reimbursement rules and adherence requirements, increasing demand for hub and patient-support services. Competition is shifting toward integrated offerings that combine value communication, payer strategy, analytics, affordability support and digital engagement.[87][89]
- M&A
- M&A activity is broadening service portfolios and adding market-access capabilities to healthcare communications and data businesses. In January 2025, Klick Health acquired Peregrine Market Access to strengthen its value, access and reimbursement offering; in 2026, GrowthCurve Capital acquired a majority stake in TailorMed, a medication-access, affordability and adherence platform.[89][39]
- Regulation
- In the United States, CMS issued a final rule on November 5, 2026, codifying Medicare Drug Price Negotiation Program policies for initial price applicability year 2029 and beyond. CMS also reported that all 15 drugs selected for the third negotiation cycle had participating manufacturers, with negotiated prices scheduled to take effect in 2028.[62]
- Latest news
- The most recent major regulatory development identified was CMS’s November 5, 2026 final rule for Medicare drug-price negotiation from 2029 onward. The rule formalizes policies as the program expands beyond its initial 2026 implementation, increasing the importance of pricing, evidence generation and payer-access strategy for manufacturers.[62]
02 Ranking
Top 10 Companies in the Market Access Pharmaceutical Industry
The leading companies in the market access pharmaceutical industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 10, 2026 · Next review December 10, 2026
Verdict
ZS leads Gitnux's 2026 market access pharmaceutical ranking with an Overall score of 9.6, with market access, pricing and value strategy analytics for pharma and life sciences. IQVIA is the highest-ranked data and analytics provider at 9.5, driven by 13.4% operating margin signal and market access data plus analytics and technology.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in market access consulting
ZS
US
Ranked #1 · 9.6 · Market access consulting
Why we picked it: It ties market access to pricing and value strategy through analytics focused on pharma and life sciences.
Leader in market access data & analytics
IQVIA
US
Ranked #2 · 9.5 · Market access data & analytics
Why we picked it: It combines market access data, analytics and technology, with a 13.4% operating margin signal reported.
Leader in pricing and reimbursement services
EVERSANA
US
Ranked #3 · 9.2 · Pricing and reimbursement services
Why we picked it: Its segment covers market access strategy plus RWE and HEOR alongside pricing and reimbursement work.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
Sort by
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | ZS Market access consulting · US | 9.6 | 9.5 | 9.9 | 9.9 | 9.9 | |
Company snapshot · ZS · Data as of November 10, 2026 ZS provides market access, pricing, value strategy and analytics for pharma and life sciences.[38]
| |||||||
| 2 | IQVIA Market access data & analytics · US | 9.5 | 9.9 | 8.5 | 9.2 | 9.9 | |
Company snapshot · IQVIA · Data as of November 10, 2026 IQVIA combines market access data, analytics, technology, operations and strategy.[20]
| |||||||
| 3 | EVERSANA Pricing and reimbursement services · US | 9.2 | 9.5 | 9.5 | 9.9 | 8.5 | |
Company snapshot · EVERSANA · Data as of November 10, 2026 EVERSANA offers market access strategy, RWE, HEOR, pricing and reimbursement solutions.[90]
| |||||||
| 4 | OPEN Health HEOR and HTA services · GB | 8.7 | 8.2 | 9.1 | 9.2 | 8.5 | |
Company snapshot · OPEN Health · Data as of November 10, 2026 OPEN Health supports global payer, HTA, pricing, reimbursement and market access strategies.[91]
| |||||||
| 5 | Syneos Health Integrated clinical and commercial · US | 8.4 | 9.5 | 8.7 | 7.0 | 7.0 | |
Company snapshot · Syneos Health · Data as of November 10, 2026 Syneos Health provides integrated clinical development and commercial solutions for biopharma companies.[92]
| |||||||
| 6 | Lumanity Market access, HEOR and payer engagement · US | 8.4 | 8.2 | 9.1 | 9.2 | 8.5 | |
Company snapshot · Lumanity · Data as of November 10, 2026 Lumanity reports more than 60 dedicated market access professionals and global access capabilities.[93]
| |||||||
| 7 | Trinity Life Sciences Pricing, reimbursement and market access consulting · US | 8.2 | 8.2 | 9.1 | 9.2 | 7.0 | |
Company snapshot · Trinity Life Sciences · Data as of November 10, 2026 Trinity aligns product value with payer priorities, reimbursement pathways and stakeholder needs.[94]
| |||||||
| 8 | Certara Market access analytics, HEOR and evidence modeling · US | 8.2 | 8.2 | 8.2 | 8.8 | 8.5 | |
Company snapshot · Certara · Data as of November 10, 2026 Certara's Evidence and Access group provides pricing, HEOR, RWE and market access services.[95]
| |||||||
| 9 | ADVI US market access, reimbursement and policy strategy · US | 8.2 | 7.0 | 9.1 | 9.9 | 7.0 | |
Company snapshot · ADVI · Data as of November 10, 2026 ADVI combines market access analytics, real-world data, HEOR and reimbursement strategy.[96]
| |||||||
| 10 | Precision AQ Market access strategy and reimbursement communications · US | 7.3 | 7.0 | 7.0 | 7.4 | 8.5 | |
Company snapshot · Precision AQ · Data as of November 10, 2026 Precision AQ develops coverage, access and reimbursement strategies for pharmaceutical products.[97]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 10, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 10). Top 10 companies in the market access pharmaceutical industry. In Market Access Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/market-access-pharmaceutical-industry-statistics/#top-companies
report visual · Comparison
Number of countries in scope where newer pharmaceutical products are registered (113 low- and middle-income countries)
Roche — Phesgo leads with 52.
Roche — Phesgo52
Johnson & Johnson — COVID-19 vaccine41
Novartis — Leqvio41
Pfizer — Comirnaty39
Roche — Polivy39
GSK — Tivicay PD31
source-verifiedaccesstomedicinefoundation.org
03 Trends & forecasts
Top 10 Market Access Pharmaceutical Industry Trends & Forecasts 2027
What is changing in the market access pharmaceutical industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Medicine spending accelerates globally
High confidenceGlobal medicine spending is projected to exceed $2.6 trillion by 2030, with annual growth of 5%–8% through the decade. IQVIA identifies the United States, other developed markets and Pharmerging countries as the main contributors to growth.[20]
Forecast 2027: In 2027, rising medicine utilization will expand demand for pricing, reimbursement, forecasting and patient-access services. Growth should remain strongest in high-cost specialty therapies and faster-growing emerging markets.
02Innovative launches intensify access work
High confidenceFDA’s CDER approved 46 novel drugs in 2025, including 34 new molecular entities and 12 biologics. Twenty of the 46 approvals were first-in-class, increasing the need for early value communication, evidence planning and payer education.[58]
Forecast 2027: In 2027, market-access teams will increasingly be involved before launch to prepare comparative-evidence packages, budget-impact models and payer positioning for novel products.
03Rare-disease access complexity rises
High confidenceExactly 23 of FDA CDER’s 46 novel drug approvals in 2025 were for orphan diseases. Rare-disease products commonly require specialized reimbursement pathways, diagnostic coordination and patient-support services.[58]
Forecast 2027: By 2027, rare-disease access programs will place greater emphasis on diagnosis acceleration, hub services, specialty distribution and documentation of outcomes in small populations.
04Biosimilar competition expands
High confidenceFDA reported 18 biosimilar approvals by CDER in 2025, bringing the cumulative total to 81 biosimilars for 20 reference products since 2015. FDA also reported that biologics represented only 5% of U.S. prescriptions but 51% of total drug spending in 2024.[58]
Forecast 2027: In 2027, biosimilar launches will increase demand for formulary strategy, switching evidence, contracting analysis and provider education, particularly in oncology, immunology and endocrinology.
05Medicare negotiation becomes structural
High confidenceCMS’s November 5, 2026 final rule codifies Medicare drug-price negotiation policies for initial price applicability year 2029 and beyond. CMS can select up to 20 drugs for the 2029 cycle and each subsequent cycle.[62]
Forecast 2027: In 2027, manufacturers will intensify negotiation-readiness work, including therapeutic-alternative analysis, evidence submission, lifecycle planning and scenario modeling for maximum fair prices.
06Negotiated net prices gain importance
High confidenceCMS estimated that negotiated prices for the first 10 selected Medicare drugs would have reduced 2023 spending by approximately $6 billion, or 22%, if they had applied that year. The 2026 final rule also requires CMS to consider manufacturer-specific information and evidence on therapeutic alternatives.[62]
Forecast 2027: In 2027, access strategy will focus less on list-price positioning alone and more on net-price corridors, rebate exposure, indication sequencing and defensible comparative-value evidence.
07Patient affordability support broadens
High confidenceMedicare Part D introduced a $2,000 annual out-of-pocket cap in 2025, while CMS projected that the redesigned benefit would reduce annual out-of-pocket prescription spending by approximately $7.4 billion in 2025. The cap increases the importance of benefit navigation and payment-support services for high-cost medicines.[62]
Forecast 2027: In 2027, manufacturers and service providers will expand affordability screening, payment-plan navigation and coordination with pharmacies and plans as benefit designs continue to shift financial responsibility.
08Prior authorization remains access friction
High confidenceThe 2025 AMA physician survey found that 26% of physicians reported that prior authorization had led to a serious adverse event for a patient. Only 33% believed insurers’ latest prior-authorization pledge would make a meaningful difference.[98]
Forecast 2027: In 2027, prior-authorization support will remain a major service line, with greater use of electronic submissions, status tracking, appeal automation and documentation support rather than a rapid disappearance of utilization management.
09EU joint assessments reshape evidence
High confidenceFrom January 12, 2025, new cancer medicines and advanced therapy medicinal products became subject to EU-level joint clinical assessments. The 2025–2027 scope covers new active substances for cancer and advanced therapy medicinal products, with results informing national pricing and reimbursement decisions.[99]
Forecast 2027: In 2027, European launch planning will increasingly require coordinated clinical evidence packages that can serve both the EU joint assessment and national economic and reimbursement processes.
10Payer evidence requirements deepen
High confidenceCMS’s negotiation framework requires manufacturers to submit information on non-Federal average manufacturer price and other manufacturer-specific factors, while interested parties may submit evidence on selected drugs and therapeutic alternatives. CMS also considers comparative-effectiveness evidence in negotiations.[62]
Forecast 2027: In 2027, health-economic modeling, comparative-effectiveness research and real-world evidence will move earlier into development plans, especially for products facing negotiation or crowded therapeutic classes.
04 Statistics
Technology & Innovation
AI adoption affects pricing and access work quickly: 59% of European respondents cited AI as most affected in 2025, and 69% expected AI for pricing/access modelling within two to three years.
AI in the market access pharmaceutical industry
- 59% of European pharmaceutical market-access respondents identified market access as their organisation’s most affected function from artificial intelligence in 2025.[1]
- 44% of European pharmaceutical market-access respondents reported structural artificial-intelligence implementation in their organisations in 2025.[1]
- 50 European pharmaceutical market-access executives and senior leaders participated in a survey of artificial-intelligence adoption conducted from June to November 2025.[1]
- 69% of surveyed pharmaceutical companies expected to use artificial intelligence for pricing and access modelling or optimisation within two to three years.[2]
- 92.2% of managed-care survey respondents agreed that artificial intelligence would be incorporated into more than half of prior-authorization reviews.[1]
- 24% of surveyed pharmaceutical companies expected to use artificial intelligence for value messaging and communications within two to three years.[2]
Digital Transformation in the pharmaceuticals and biotech sector (sector benchmark)
- 45% of pharmaceutical companies surveyed were pursuing digitalization as an innovation or technology in 2024.[3]
- 58.1% of global pharmaceutical-industry survey respondents were in the pilots or systematic-ongoing-actions stages of Pharma 4.0 adoption in 2023.[4]
- 13% of clinical-research organizations surveyed reported a comprehensive AI-driven digital programme in 2024.[5]
- 15.1% of global pharmaceutical-industry survey respondents reported that Pharma 4.0 digital transformation had not started in 2023.[4]
- 35% of clinical-research organizations surveyed were piloting digital technologies in 2024, up from 29% in 2019.[5]
Technology Adoption in the pharmaceuticals and biotech sector (sector benchmark)
- 63% of global biopharma respondents had adopted robotics and automation in 2023.[6]
- 55% of biopharma AI adopters reported using AI in process development in 2024.[7]
- 70% of global biopharma respondents had adopted an R&D data platform in 2023.[6]
- 37% of small biopharma respondents reported that more than 60% of their R&D laboratory instruments had automated data capture in 2024.[8]
- 59% of global biopharma respondents had adopted artificial intelligence or machine learning in 2023.[6]
Cloud Computing in the pharmaceuticals and biotech sector (sector benchmark)
- 18% of global biopharma respondents had adopted cloud-based scientific software or SaaS in 2023.[6]
- 77% of life-sciences commercial IT leaders reported investing primarily in cloud infrastructure in 2024.[9]
- 49% of biopharma survey respondents reported using cloud computing to facilitate day-to-day work in 2021.[10]
- 23% of small biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[7]
- 17% of large biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[7]
Big Data in the pharmaceuticals and biotech sector (sector benchmark)
- 33% of biopharma survey respondents reported using data lakes in day-to-day operations in 2021.[10]
- 48% of pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[3]
- 43% of small and midsize pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[3]
- 55% of large pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[3]
- 49% of clinical-research survey respondents reported using AI and big-data analytics in drug development in 2024.[5]
- 68% of pharmaceutical companies surveyed planned to use advanced analytics in 2024.[11]
IoT in the pharmaceuticals and biotech sector (sector benchmark)
- 37% of biopharma organizations globally reported using IoT in a project or with a third party in Deloitte’s 2021 survey.[10]
- 21.4% of IoT-using SMEs in the European healthcare industrial ecosystem applied IoT to predictive maintenance of production assets in 2023.[12]
- 9% of European pharmaceutical supply-chain organizations were already using IoT in 2024, while 23% planned to implement it, according to Miebach’s survey.[13]
05 Statistics
Data & Analytics
Data readiness remains a bottleneck: 96% of life-sciences respondents said their data was not well-structured or AI-ready for scaling in 2025, and 73% reported significant data quality issues in 2025.
Business intelligence in the market access pharmaceutical industry
- 37% of pharma executives cited data accuracy as an internal-data concern in 2024.[11]
- 15% of pharma executives cited data completeness as an internal-data concern in 2024.[11]
- 66% of life-sciences respondents had well-defined enterprise-wide AI strategies in 2026.[14]
- 41% of pharma executives said their teams always used spreadsheets for revenue management in 2024.[11]
- 96% of pharma companies leveraged external data sources for business decisions in 2024.[11]
- 64% of pharma executives purchased benchmarking data to support decision-making in 2024.[11]
Data analytics in the market access pharmaceutical industry
- 42% of life-sciences organizations consistently used analytics for value-based contracting in 2021.[15]
- 42% of life-sciences respondents ranked genomic data among their most useful data sources in 2021.[15]
- 60% of life-sciences organizations consistently used analytics for marketing forecasting in 2021.[15]
- 65% of life-sciences respondents ranked electronic health-record data as their most useful data source in 2021.[15]
- 64% of pharmaceutical-company respondents consistently used analytics for value-based contracting in 2021.[15]
- 50% of life-sciences organizations used external vendors for R&D analytics projects in 2021.[15]
Data Quality in the pharmaceuticals and biotech sector (sector benchmark)
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 73% reported significant data quality issues in 2025.[16]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 96% said their data was not well-structured or AI-ready for scaling in 2025.[16]
- Across 500 pharmaceutical and biotechnology executives globally, 44% said their organization was prepared on data quality and completeness in 2025.[17]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 81% identified data quality as their top data issue for the next 12 months in 2025.[16]
- Across 125 senior U.S. life-sciences leaders, 81% said accuracy and confidence in data were critical components of AI success in biopharma in 2026.[16]
Data Governance in the pharmaceuticals and biotech sector (sector benchmark)
- Across 500 pharmaceutical and biotechnology executives globally, 54% said their organization was prepared on data governance in 2025.[17]
- Across 200 global life-sciences R&D respondents, 49% called for more data-governance frameworks to make data FAIR at scale in 2024.[18]
- Across 200 global life-sciences R&D respondents, 51% identified maintenance and management of data standards and ontologies as a key FAIR-data need in 2024.[18]
- Across 11 pharmaceutical regulatory organizations, 9% reported a comprehensive approach to onboarding standards such as IDMP and XEVMPD, with regular source qualification, connected systems and data cleaning in 2023.[19]
- Across 200 global life-sciences R&D respondents, 46% called for templates for standardization and metadata to make data FAIR at scale in 2024.[18]
KPIs in the market access pharmaceutical industry
- 61% of surveyed pharmaceutical companies differentiated between metrics and KPIs in 2024.[1]
- 65% of surveyed pharmaceutical companies tracked documents created or updated as a KPI in 2024.[1]
- 58% of surveyed pharmaceutical companies tracked abandonment rate among query-related metrics in 2024.[1]
- 55% of surveyed pharmaceutical companies tracked escalation rate as a KPI in 2024.[1]
- 55% of surveyed pharmaceutical companies tracked contact types as a KPI in 2024.[1]
- 77% of surveyed pharmaceutical companies tracked response turnaround time as a KPI in 2024.[1]
06 Statistics
Strategy & Growth
Access strategy increasingly depends on AI modelling use cases and payer evidence. US net prices grew 10.6% in 2025 and IQVIA forecast 4.5%–7.5% net-price spending growth through 2030.
Growth in the market access pharmaceutical industry
- 2.4% was the average annual growth in U.S. retail prescription-drug use during the five years through 2025.[20]
- 10.6% was the growth rate of the U.S. pharmaceutical market at net prices in 2025, according to IQVIA.[20]
- US$1,031 billion was the estimated U.S. pharmaceutical market at list prices in 2022, according to IQVIA’s updated model.[20]
- 4.5% to 7.5% is IQVIA’s forecast for annual U.S. medicine-spending growth at net prices through 2030.[20]
- 13% was the increase in U.S. prescription-medicine use, measured in defined daily doses, during the five years through 2025.[20]
- 6% to 9% is IQVIA’s forecast for annual U.S. medicine-spending growth at list prices through 2030.[20]
Differentiation in the market access pharmaceutical industry
- 69% of surveyed pharmaceutical companies identified pricing and access modeling or optimization as an anticipated artificial-intelligence use case for market access.[2]
- 21% of surveyed pharmaceutical companies expected to use artificial intelligence for market access within two to three years in 2025.[2]
- 71% of specialty drugs were associated with better launch performance in Deloitte’s analysis of pharmaceutical launches.[10]
- 47% of drug-launch failures were attributed to inadequate understanding of market and customer needs in Deloitte’s analysis.[10]
- 41% of drug-launch failures were attributed to poor product differentiation in Deloitte’s analysis of U.S. pharmaceutical launches.[10]
- 57% of surveyed pharmaceutical companies identified patient or provider segmentation as an anticipated artificial-intelligence use case for market access.[2]
Mergers and acquisitions in the market access pharmaceutical industry
- 23% was the decline in announced life-sciences M&A deals in the fourth quarter of 2024 versus the fourth quarter of 2023.[20]
- US$74.9 billion was the total pharmaceutical M&A transaction value in 2010, according to the ASPE study.[21]
- 267 pharmaceutical-sector mergers and acquisitions occurred in 2016, the highest annual count reported by the U.S. Department of Health and Human Services for 2010–2023.[22]
- 15 pharmaceutical acquisitions valued above US$1 billion occurred in 2024, according to a U.S. life-sciences market review citing Stifel data.[23]
- 85.3% of pharmaceutical M&As from 2018 to 2023 involved a target company whose leading asset was a brand drug, when the asset type was known.[21]
- 24.3% higher odds of entering shortage within two years were associated with drugs involved in an M&A compared with similar drugs not involved in an M&A.[22]
Strategic partnerships in the market access pharmaceutical industry
- US$161.5 billion was the aggregate potential value of licensing deals with disclosed financial terms in 2022.[20]
- US$2.7 billion was the potential value of Novo Nordisk’s 2023 licensing deal with Aspect Biosystems for bioprinted tissue therapeutics.[20]
- US$272 million was the median licensing-deal value in 2024, up 45% from 2023, according to IQVIA.[20]
- 13% was the growth in licensing deals in 2023, according to IQVIA’s analysis of pharmaceutical deal activity.[20]
- US$152.2 billion was the aggregate potential value of licensing deals with disclosed financial terms in 2024.[20]
- More than 30% of assets in-licensed by big pharmaceutical companies in 2024 originated in China, according to IQVIA.[20]
07 Statistics
People & Workforce
Workforce capacity and adoption risk show up in managed-markets staffing. Managed-markets marketing headcount rose 10% year over year in 2025 in repeat pharmaceutical firms in the US.
Hiring in the market access pharmaceutical industry
- 10% was the 2025 year-over-year headcount increase in managed-markets marketing across repeat pharmaceutical firms in the United States.[24]
- 64% of managed-markets respondents identified government policy and regulation as the market trend with the greatest potential to constrain access and shape staffing decisions in 2026.[24]
- 14% of managed-markets respondents identified benefit design as a market trend with potential to limit pharmaceutical access and influence staffing in 2026.[24]
- 8% was the 2025 year-over-year headcount increase in contracting administration across repeat pharmaceutical firms’ managed-markets organizations in the United States.[24]
- 5% was the 2025 year-over-year headcount increase in government policy and advocacy across repeat pharmaceutical firms’ managed-markets organizations in the United States.[24]
Employee retention in the market access pharmaceutical industry
- 8 was the mean relative weight assigned to a brand not being seen as a priority by global market access stakeholders reporting frustrations with internal impact in 2024.[25]
- 42% of pharma employees were not fully engaged with a new digital solution their organization was adopting in 2024, creating a workforce-adoption risk for market access and related functions.[26]
- 26 was the mean relative weight assigned to lack of budget by global market access stakeholders reporting frustrations with internal impact in 2024.[25]
- 31% of pharma employees said their line manager communicated only sometimes or poorly in 2024, indicating a potential management-related retention pressure.[26]
- 40% of pharma employees were not champions for a compliance programme they had recently undertaken in 2024, indicating incomplete engagement with a core pharmaceutical-workforce requirement.[26]
Remote Work in the pharmaceuticals and biotech sector (sector benchmark)
- Across U.S. chemical and pharmaceutical manufacturers, 5.7% of positions were fully remote in the 2024 hiring outlook survey.[27]
- Among privately held life-sciences companies surveyed, 21.7% had some portion of their workforce fully remote in 2025.[28]
- Across U.S. life sciences companies, 65.9% reported implementing, expanding, or considering remote-work options for at least some employees in 2023.[29]
- Among life-sciences companies with remote-work options, 50.0% cited competition with technology and other industries as a reason for their policy in 2023.[29]
Hybrid Work in the pharmaceuticals and biotech sector (sector benchmark)
- Among life-sciences CEOs, 83% expected corporate employees whose roles were traditionally office-based to work in a hybrid environment three years after the 2024 survey.[14]
- Across U.S. chemical and pharmaceutical manufacturers, 44.5% of positions were fully hybrid in the 2024 hiring outlook survey.[27]
- Among surveyed life-sciences employers in the BioHealth Capital Region, 60% expected at least a hybrid workforce after the pandemic in 2021.[30]
- Among surveyed life-sciences companies in the MassBio Human Resources Roundtable, 97% planned to implement hybrid work models for the long term in 2022.[31]
Upskilling in the market access pharmaceutical industry
- 38% of pharmaceutical-company respondents identified the increasingly challenging and sophisticated payer environment as a key market access challenge in 2018.[32]
- 19% of pharmaceutical-company respondents said their organization had no official definition of market access or that they were unsure of its definition in 2018.[32]
- 9% of pharmaceutical-company respondents said their Clinical Development teams received market access training in 2018.[32]
- 66% of pharma employees said training was generally effective in 2024.[26]
- 29% of pharma employees lacked the clarity needed to adopt new digital solutions effectively in 2024.[26]
Employee Engagement in the pharmaceuticals and biotech sector (sector benchmark)
- Across the Culture Amp pharmaceuticals benchmark, 17% of employees disagreed that they had seen positive changes based on recent employee survey results in July 2026.[33]
- Across the Culture Amp pharmaceuticals benchmark, 91% of employees agreed they understood how their work contributed to company goals in July 2026.[33]
- Across the Culture Amp pharmaceuticals benchmark, 18% of employees were thinking of or actively seeking another job in July 2026.[33]
- At Amneal Pharmaceuticals, global employee engagement reached 88% in the company’s 2024 reporting year.[34]
DEI in the market access pharmaceutical industry
08 Statistics
Customer & Sales
Patient-support adherence and experience metrics show the operational stakes for access services: 72% remained adherent six months after enrollment, and adherence was 85% across studied programs covering 32 brands.
Customer experience in the market access pharmaceutical industry
- 64 CXQ was Lilly’s global pharmaceutical customer-experience score in 2024.[37]
- −57% was the lowest pharmaceutical-company Net Promoter Score in ZS’s 2025 U.S. healthcare-provider survey.[38]
- 64 CXQ was J&J Innovative Medicine’s global pharmaceutical customer-experience score in 2024.[37]
- −10% was the average Net Promoter Score for pharmaceutical companies in ZS’s 2025 U.S. healthcare-provider survey.[38]
- 26% was the highest pharmaceutical-company Net Promoter Score in ZS’s 2025 U.S. healthcare-provider survey.[38]
Customer retention in the market access pharmaceutical industry
- 18% of U.S. mail-order pharmacy customers said they would probably or definitely switch pharmacies within the next year in 2023.[39]
- 72% of patients in one pharmaceutical therapy-support program remained adherent six months after enrollment.[40]
- 85% was the adherence rate reported across a global pharmaceutical company’s patient-support programs covering 32 brands.[9]
- 80% was the compliance rate reported across a global pharmaceutical company’s patient-support programs covering 32 brands.[9]
- 300,000 patients were enrolled across 32 brands and seven therapy areas in a global pharmaceutical patient-support program.[9]
Customer acquisition in the market access pharmaceutical industry
- 91% was the enrollment rate reached by a pharmaceutical patient-services program after adopting the PhilRx platform.[41]
- 8% of patients had ever used a pharmaceutical patient-support program in Phreesia’s survey.[42]
- 3% of potentially eligible patients were using pharmaceutical patient-support programs in Phreesia’s survey.[42]
- 59% of patients reported little or no knowledge of pharmaceutical patient-support programs in Phreesia’s survey.[42]
- 44% of patients wanted to learn about pharmaceutical patient-support programs online, compared with 10% who had learned about them online.[42]
Customer loyalty in the market access pharmaceutical industry
- −3 was the approximate average Net Promoter Score for pharmaceutical firms reported by Bain.[43]
- More than 70% of managed-markets respondents rated Pfizer’s pharmaceutical-manufacturer relationship as collaborative or strategic in HIRC’s 2026 research.[24]
- More than 70% of managed-markets respondents rated Novo Nordisk’s pharmaceutical-manufacturer relationship as collaborative or strategic in HIRC’s 2026 research.[24]
- 77% of managed-markets respondents rated Lilly’s pharmaceutical-manufacturer relationship as collaborative or strategic in HIRC’s 2026 research.[24]
- 40% of a doctor’s drug recommendations were linked to overall experience with the pharmaceutical firm in Bain research.[43]
Lead generation in the market access pharmaceutical industry
- 56% of pharmaceutical marketing leaders cited building brand awareness and recognition as a digital-marketing objective in 2025.[44]
- 39% of pharmaceutical marketing leaders cited supporting sales teams through lead generation and educational materials as a digital-marketing objective in 2025.[44]
- 18% of pharmaceutical marketing leaders cited gathering competitive intelligence as a digital-marketing objective in 2025.[44]
- 17% of pharmaceutical marketing leaders cited protecting and enhancing brand reputation as a digital-marketing objective in 2025.[44]
- 1 in 11 pharma marketing job postings in a 2026 sample explicitly named email and nurture as a channel.[45]
09 Statistics
Marketing & Brand
Market access and access friction intersect with digital communications. In a 2026 survey, 42% of respondents represented agencies and 35% represented pharma brands.
Marketing in the market access pharmaceutical industry
- 47% of respondents in the 2026 pharma marketing survey worked in oncology.[46]
- More than 80% of pharma marketers relied on market research to inform marketing decisions in an M3 survey.[47]
- 42% of respondents in the 2026 pharma marketing survey represented agencies, compared with 35% representing pharma brands.[46]
- 80% of pharma marketers expected their 2026 budgets to remain stable or increase, based on a survey conducted in late 2025.[46]
- 60% of brand-side pharma marketers surveyed worked for companies with annual revenue above $10 billion.[46]
Digital marketing in the market access pharmaceutical industry
- 30.8% of pharmaceutical and medicine manufacturers’ U.S. advertising spend was forecast to be digital in 2025.[48]
- 14.2% was the forecast 2024 growth rate for U.S. pharma digital advertising spending.[49]
- $19.45 billion was forecast to be spent on online marketing by the U.S. pharmaceutical sector in 2024.[49]
- 27.3% of pharmaceutical and medicine manufacturers’ U.S. advertising spend was digital in 2023.[48]
- 88% of the broader U.S. healthcare industry’s digital advertising spending was attributed to pharma in 2024.[49]
Branding in the market access pharmaceutical industry
- 70% of pharma respondents reported medium or high impact from launch personalization efforts, supporting individualized brand engagement.[38]
- 38% of pharma launch-personalization survey respondents worked for mid-size pharmaceutical companies.[38]
- 58% of Americans said how a pharmaceutical company communicates is as important as how effective its treatments are.[50]
- 39% of pharma launch-personalization survey respondents worked for large pharmaceutical companies.[38]
- 16% of pharma launch-personalization survey respondents worked for small or emerging pharmaceutical companies.[38]
Influencer Marketing in the pharmaceuticals and biotech sector (sector benchmark)
- 50% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their prescribing choices in 2024.[52]
- 4.5% of high-engagement prescription-drug promotion posts across Facebook, Instagram, TikTok and YouTube came from pharmaceutical companies in the United States in 2025.[53]
- 10% of healthcare and pharmaceutical marketers said they did not invest in creator or influencer marketing in 2026, globally.[54]
- 29% of healthcare and pharmaceutical marketers reported dedicated but flat budgets for creator or influencer marketing in 2026, globally.[54]
- 44% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their perception of a medication in 2024.[52]
10 Statistics
Operations & Execution
Execution timing and system integration drive outcomes across submission and access timelines. The average time from EMA approval to reimbursement was 434 days in 2023 across in-scope European markets.
Process optimization in the market access pharmaceutical industry
- 5.0 working weeks was the 2024–2025 median duration from last patient visit to database lock in pharmaceutical regulatory submissions.[55]
- 85% of large pharmaceutical companies surveyed had implemented AI solutions in 2026, compared with 28% of medium-sized and 32% of small companies.[1]
- 8.0 working weeks was the 2020 median duration from last patient visit to database lock in pharmaceutical regulatory submissions.[55]
- 13 of 22 pharmaceutical companies with structural AI implementation reported market access as the most impacted function in 2026.[1]
- 10.2 working weeks was the best-in-class total duration from last patient visit to regulatory filing in 2024–2025, based on 62 pharmaceutical companies globally.[55]
Operational efficiency in the market access pharmaceutical industry
- 90 days was the average pharmaceutical-company filing time in EU4 and UK markets in 2023.[56]
- 434 days was the average time from EMA approval to reimbursement across the in-scope European markets in 2023.[56]
- 29% of innovative medicines were fully available through public reimbursement across the EU in 2024.[56]
- 29% of the total time between EMA approval and reimbursement was attributed to manufacturers’ time to file for pricing and reimbursement in 2023.[56]
- 578 days was the average time from approval to patient access for innovative medicines across 27 EU member states in 2024.[56]
Quality management in the market access pharmaceutical industry
- 43% of life-sciences manufacturing respondents identified integration of new and existing data systems as their main operational challenge in 2022.[57]
- 46% of pharmaceutical companies reported medium-to-advanced digital data management with integrated electronic data solutions in a process-verification survey.[4]
- 77% of pharmaceutical manufacturing respondents identified data integrity as a leading concern when selecting smart equipment and software providers in 2022.[57]
- 5% of life-sciences manufacturing respondents reported moving toward a fully adaptive plant in 2022.[57]
- 48% of pharmaceutical manufacturing respondents identified GxP compliance as a leading concern when selecting smart equipment and software providers in 2022.[57]
Supply chain in the market access pharmaceutical industry
- 64 ongoing CDER drug shortages were recorded by the FDA in the United States during 2015.[58]
- 48 ongoing FDA-tracked drug shortages were recorded in the United States during 2022, comprising 43 CDER shortages and 5 CBER shortages.[58]
- 74 ongoing CDER drug shortages were recorded by the FDA in the United States during 2014.[58]
- 20 companies held certificates to supply active pharmaceutical ingredients for injectable corticosteroids sold in the European Union in 2024.[59]
- 113 ongoing FDA-tracked drug shortages were recorded in the United States during 2024, comprising 88 CDER shortages and 25 CBER shortages.[58]
Outsourcing / Offshoring in the pharmaceuticals and biotech sector (sector benchmark)
- 12% of total API volume used in the United States was produced domestically in 2024, with most supply coming from India and the European Union.[60]
- 40% of surveyed pharma and biotech CDMO decision-makers identified small-molecule API as the most outsourced product in July 2024.[61]
- 74% of surveyed pharmaceutical and biotech R&D leaders ranked patient recruitment among the top five drug-development activities likely to be outsourced in 2023.[3]
- 67% of global biotech and pharma companies outsourced pharmacovigilance operations in 2024, according to an IQVIA industry report.[20]
- 54% of global biotech and pharma companies outsourced regulatory activities in 2024, according to an IQVIA industry report.[20]
11 Statistics
Finance & Pricing
Negotiated net prices and outcomes evidence drive savings. CMS estimated about $6 billion in 2023 spending reduction, or 22%, for 10 selected drugs under the first Medicare negotiation cycle.
Pricing strategy in the market access pharmaceutical industry
- 4.5% was the average annual increase in U.S. branded-drug net prices from 2007 to 2018.[53]
- 439% was the increase in list prices for multiple-sclerosis treatments in the U.S. from 2007 to 2018.[53]
- 278% was the increase in U.S. list prices for lipid-lowering drugs from 2007 to 2018.[53]
- 95% was the increase in U.S. net prices for lipid-lowering drugs from 2007 to 2018.[53]
- 60% was the increase in U.S. branded-drug net prices from 2007 to 2018 across 602 products.[53]
Cost reduction in the market access pharmaceutical industry
- $1.0 billion was the estimated annualized U.S. Medicare savings from negotiated prices for Farxiga in the first negotiation cycle.[62]
- 38% was the negotiated discount from list price for Imbruvica under the U.S. Medicare 2026 negotiation cycle.[63]
- $1.6 billion was the estimated annualized U.S. Medicare savings from negotiated prices for Eliquis, the highest-spending selected product in the first cycle.[62]
- $1.5 billion was the estimated annualized U.S. Medicare savings from negotiated prices for Jardiance in the first negotiation cycle.[62]
- $600 million was the estimated annualized U.S. Medicare savings from negotiated prices for NovoLog and Fiasp in the first negotiation cycle.[62]
Profitability in the market access pharmaceutical industry
- $7.771 billion was Pfizer’s net income attributable to common shareholders in 2025.[64]
- $65.179 billion was Eli Lilly’s worldwide revenue in 2025.[64]
- 74.8% was Merck’s gross margin in 2025.[65]
- 15% was the year-over-year decrease in Merck’s fourth-quarter 2025 R&D expense.[65]
- $34.124 billion was Eli Lilly’s worldwide revenue in 2023.[64]
Financial planning in the market access pharmaceutical industry
- $45.043 billion was Eli Lilly’s 2024 revenue used as the prior-year base for financial planning.[64]
- $8.031 billion was Pfizer’s 2024 net income used as the prior-year comparison in financial planning.[64]
- $7.771 billion was Pfizer’s 2025 net income used in corporate financial planning and resource allocation.[64]
- $34.124 billion was Eli Lilly’s 2023 revenue used as the two-year historical base for financial planning.[64]
- 4.5% to 7.5% is IQVIA’s forecast range for U.S. medicine spending growth at net prices through 2030.[20]
12 Statistics
Product & Service
Access programs concentrate on payer support and availability. 85.5% of pharmaceutical access programs studied were implemented where the company had commercial products registered.
Product development in the market access pharmaceutical industry
- 23% was the decline in median six-month cumulative sales for innovative launches after 2020 compared with pre-2020 levels.[20]
- 85.5% of pharmaceutical access programs studied were implemented in countries where the company had commercial products registered.[66]
- 57% of US drug-launch failures were attributed to limited market access in launches analyzed through 2021.[10]
- US$2 billion is the average cost of bringing a pharmaceutical asset to market, according to 2022 analysis of the US pharmaceutical industry.[10]
- 18 precision medicines were approved by the FDA in 2024, according to IQVIA’s launch-investment analysis.[20]
Product lifecycle in the market access pharmaceutical industry
- 50% of US prescriptions for newly launched brands had full manufacturer payer support in 2022.[20]
- 84% was the increase in median annual launch treatment cost for non-oncology orphan medicines from 2014 to 2023.[20]
- More than 60% of new patients experienced durable launch-year rejections for many US brands in IQVIA’s modern-launch analysis.[20]
- US$60 million was the average first-year revenue for pharmacy-benefit launch products in 2022, excluding vaccines and GLP-1 medicines.[20]
- US$140 million was the average first-year revenue for comparable US pharmacy-benefit launch products in 2018, excluding vaccines and GLP-1 medicines.[20]
After-sales in the market access pharmaceutical industry
- 22.0% lower adalimumab discontinuation was associated with participation in a manufacturer patient-support program in a US cohort.[1]
- 50% of commercially insured US branded oral-oncology patients ultimately filled treatment after initial access barriers during 2020–2023.[20]
- 12.2% higher drug costs were observed for US adalimumab patients participating in a patient-support program.[1]
- 43.7% of US adalimumab patient-support-program participants achieved at least 80% adherence, compared with 25.7% of nonparticipants.[1]
- 9% lower total healthcare costs were observed for US adalimumab patients participating in a patient-support program.[1]
Value proposition in the market access pharmaceutical industry
- 80% of surveyed US payers identified availability of evidence to track outcomes as a limitation to innovative pharmaceutical contracting in 2024.[67]
- 4.4 out of 5 was the weighted payer rating for efficacy as prelaunch manufacturer-provided evidence in a 2024 US survey.[67]
- 4.1 out of 5 was the weighted payer rating for initial pricing estimates as prelaunch manufacturer-provided evidence in a 2024 US survey.[67]
- 4.1 out of 5 was the weighted payer rating for safety as prelaunch manufacturer-provided evidence in a 2024 US survey.[67]
- 10% of surveyed US payer participants frequently or always used manufacturer-developed health-economic models in 2024.[67]
13 Statistics
Sustainability & Ethics
Access strategy also runs alongside access-to-care and emissions reporting. AstraZeneca reached 90.5 million people cumulatively through access-to-healthcare programmes by 2024.
Sustainability in the market access pharmaceutical industry
- 46% of biopharma professionals considered themselves strong at improving supply-chain sustainability in 2024.[68]
- AstraZeneca reached 90.5 million people cumulatively through access-to-healthcare programmes by 2024.[69]
- 61% of pharmaceutical and medical-technology companies in the UN Race to Zero campaign had started a My Green Lab Certification in 2024.[70]
- 69% of biopharma professionals identified weak collaboration across the value chain as a barrier to sustainability in 2024.[71]
- AstraZeneca reduced waste by 13% from its 2015 baseline by 2024.[69]
ESG in the market access pharmaceutical industry
- Novartis medicines reached 296 million patients globally in 2024.[72]
- Novartis received 20 major approvals in the United States, European Union, Japan and China in 2024.[72]
- AstraZeneca reported Scope 1 and 2 emissions intensity of 2.58 tonnes CO₂e per million dollars of total revenue in 2024.[69]
- AstraZeneca reported 5,897,822 tonnes of gross Scope 3 emissions in 2024.[69]
- AstraZeneca’s senior roles were 50.6% occupied by women in 2024.[69]
Ethics in the market access pharmaceutical industry
- AstraZeneca trained 156,000 healthcare professionals cumulatively through its programmes from 2015 through 2024.[69]
- Twenty pharmaceutical companies were assessed across 113 countries in the 2024 Access to Medicine Index.[73]
- Novartis reported 100% implementation of a global access strategy for new medicines launched in 2024.[72]
- Novartis ranked first among 20 pharmaceutical companies in the 2024 Access to Medicine Index.[74]
- Novartis reported 296 million patients reached through its medicines in 2024.[72]
CSR in the market access pharmaceutical industry
- Novartis reached more than 26.3 million patients through flagship global-health programmes by the end of 2024.[74]
- Pfizer reported 49.7 million dollars in product donations in 2023.[75]
- AstraZeneca trained 127,384 healthcare workers cumulatively by 2023.[69]
- AstraZeneca provided 127 million dollars in community investment in 2024.[69]
- AstraZeneca funded 928 nonprofit organizations in 2024.[69]
Carbon footprint in the market access pharmaceutical industry
- Public biotech and pharmaceutical companies emitted 259 million tCO₂e across Scopes 1, 2 and 3 in 2023.[70]
- AstraZeneca’s Scope 1 and 2 emissions intensity was 2.58 tCO₂e per million dollars of total revenue in 2024.[69]
- AstraZeneca reduced waste by 13% against its 2015 baseline by 2024.[69]
- AstraZeneca reduced Scope 1 and 2 emissions by 77.5% against its 2015 baseline by 2024.[69]
- Scope 3 emissions were 6.5 times larger than combined Scope 1 and 2 emissions for private biotech and pharmaceutical companies in 2023.[70]
14 Statistics
Risk, Compliance & Legal
Compliance and cybersecurity risks affect the ability to scale access operations. 98% of surveyed pharmaceutical firms experienced at least one cybersecurity intrusion in the 12 months covered by Fortinet’s 2021 survey.
Compliance in the market access pharmaceutical industry
- 13 of 20 large pharmaceutical companies had comprehensive internal controls for regulatory and anti-corruption compliance in the 2022 Access to Medicine Index.[73]
- 21% was the increase in inspection-based warning letters issued to human drug manufacturing sites in the United States from fiscal year 2023 to 2024.[58]
- 6 companies newly demonstrated that sales-agent incentives were not based solely on sales volume in the 2022 Access to Medicine Index.[73]
- 90 days is the FDA target for completing current good manufacturing practice classifications of human drug facility inspections.[58]
- 58% of U.S. healthcare and life-sciences compliance leaders said developing an artificial-intelligence compliance governance structure was difficult in 2025.[76]
Risk Management in the pharmaceuticals and biotech sector (sector benchmark)
- 85% of global life science firms had a formal business continuity process covering the whole business in 2024.[77]
- 52% of middle-market life sciences companies reported having a business continuity plan in place.[78]
- 81% of middle-market life sciences companies said risk management was a top priority, rising to 90% among the fastest-growing organizations.[78]
- 90% of clinical trials managed by surveyed CROs included at least one risk-based monitoring or risk-based quality-management component in 2025.[79]
- 44% of global life science firms reported no standardized or consistently effective intellectual-property risk-management process in 2024.[77]
Cybersecurity in the pharmaceuticals and biotech sector (sector benchmark)
- 98% of surveyed pharmaceutical firms experienced at least one cybersecurity intrusion in the 12 months covered by Fortinet’s 2021 survey.[80]
- 28% of surveyed pharmaceutical businesses lost business-critical data or intellectual property because of cybersecurity incidents.[80]
- 52% of surveyed middle-market life sciences companies reported experiencing a cybersecurity breach.[78]
- 40% of surveyed pharmaceutical businesses experienced outages affecting productivity, safety, compliance, revenue, or brand image.[80]
- 27% of healthcare, biotechnology, and pharmaceutical respondents had little or no confidence in identifying where their data was stored in 2025.[81]
Data Privacy in the pharmaceuticals and biotech sector (sector benchmark)
- 66% of pharma, biotech, and medical-device respondents said patient privacy presented a challenge when complying with journal data-sharing policies in 2024.[82]
- 84% of surveyed pharmaceuticals and life sciences organizations said measuring and managing sensitive-content compliance required some to significant improvement in 2024.[83]
- 39% of surveyed pharmaceuticals and life sciences organizations said they tagged and classified around three-quarters of their unstructured data in 2024.[83]
- Stricter privacy regulation was associated with an approximately 39% reduction in R&D spending by global pharmaceutical and biotechnology firms four years after implementation.[84]
- 61% of surveyed pharmaceuticals and life sciences organizations identified GDPR as a top-two privacy and compliance focus in 2024.[83]
Crisis Management in the pharmaceuticals and biotech sector (sector benchmark)
- 61% of surveyed global life science firms identified panic buying and stockpiling as a major supply-chain risk for the following two years.[77]
- 52% of surveyed global life science firms identified contract-manufacturing issues as a major supply-chain risk for the following two years.[77]
- 40% of surveyed pharmaceutical firms maintained inventory buffers of one to three months to protect against supply-chain disruption.[85]
- 50% of surveyed global life science firms identified logistics and warehousing shortages as a major supply-chain risk for the following two years.[77]
- 48% of surveyed global life science firms identified natural disasters as a major supply-chain risk for the following two years.[77]
Governance in the market access pharmaceutical industry
- 43% of innovative pharmaceutical products approved during the preceding five years remained unregistered in Africa in 2024.[73]
- 4 of 20 large pharmaceutical companies implemented access-planning policies for all late-stage candidates in 2024.[73]
- 253 priority research-and-development projects were in the pipelines of 20 large pharmaceutical companies in the 2024 Index.[73]
- 61% of products assessed lacked equitable-access strategies in low-income countries in the 2024 Index.[73]
- 14 of 20 large pharmaceutical companies had systematic policies to plan access for all pipeline candidates from Phase II onward in 2024.[73]
15 Statistics
Globalization & Expansion
Global medicine spending and regional complexity underpin market access demand. The global pharmaceutical market was estimated at $1,583 billion in 2024 and projected to reach $2,100–$2,200 billion by 2029.
Globalization in the market access pharmaceutical industry
- $1,583 billion was the estimated global pharmaceutical market value in 2024.[86]
- $1,288 billion was the global pharmaceutical market value in 2020.[86]
- The global pharmaceutical market was projected to reach $2,100–$2,200 billion by 2029.[86]
- $1,457 billion was the global pharmaceutical market value in 2022.[86]
- $1,250 billion was the global pharmaceutical market value in 2019.[86]
Stakeholder management in the market access pharmaceutical industry
- 50% of policy-maker and health-technology-assessor respondents identified the pharmaceutical industry as a market-access stakeholder in 2016.[1]
- 63% of policy-maker and health-technology-assessor respondents identified patients as market-access stakeholders in a 2016 survey.[1]
- 25% of respondents considered patient outcomes important when defining market access in 2016.[1]
- 50% of respondents considered pharmaceutical outcomes important when defining market access in 2016.[1]
- 38% of respondents said market-access activities occurred during the post-launch phase in 2016.[1]
Distribution channels in the market access pharmaceutical industry
- Nearly 4 billion prescription claims per year were received by IQVIA for its longitudinal prescription-claims database.[20]
- 27% of total U.S. pharmaceutical sales represented manufacturer payments to entities in the distribution and financing system in 2015.[53]
- 81% of employer-based health plans had three or more formulary tiers in 2015.[53]
- 55% coverage was represented by IQVIA’s Formulary Impact Analyzer claims data from retail, mail and long-term-care pharmacies.[20]
- 77% of U.S. mail and long-term-care channels were covered at the upper end by IQVIA’s Xponent data.[20]
Key questions about the market access pharmaceutical industry
How large is the pharma market access and patient access support services market?
The global pharma hub and patient access support services market was estimated at $3.9 billion in 2025. A separate market-access-solutions estimate put the broader market at approximately $24.2 billion in 2025.
How is market access demand expected to grow through 2030?
Global medicine spending is expected to exceed $2.6 trillion by 2030 and increase at an annual rate of 5%–8% through 2030. The patient access support services market report forecasts continued expansion through 2033.
Which companies lead the market access pharmaceutical industry?
ZS leads Gitnux's 2026 market access pharmaceutical ranking with an Overall score of 9.6, with market access, pricing and value strategy analytics for pharma and life sciences. IQVIA is the highest-ranked data and analytics provider at 9.5, driven by 13.4% operating margin signal and market access data plus analytics and technology.
What technology shifts are most visible in market access work?
In 2025, 59% of European market-access respondents said market access was most affected by artificial intelligence, and 44% reported structural AI implementation. 69% of surveyed companies expected AI for pricing and access modelling or optimisation within two to three years.
How concentrated is the market access buyer base?
The Access to Medicine Index evaluates 20 of the world’s largest research-based pharmaceutical companies, indicating a concentrated client base among large originator manufacturers rather than a single concentrated services market.
What pricing mechanism is shaping negotiation outcomes most in the US?
Pricing is increasingly shaped by negotiated net prices, rebates, reimbursement limits and outcomes evidence rather than list prices alone. For the first Medicare negotiation cycle, CMS estimated 10 selected drugs would have reduced 2023 spending by approximately $6 billion, or 22%.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, November 10). Market Access Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/market-access-pharmaceutical-industry-statistics
MLA
Samuel Norberg. "Market Access Pharmaceutical Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/market-access-pharmaceutical-industry-statistics.
Chicago
Samuel Norberg. 2026. "Market Access Pharmaceutical Industry Statistics." Gitnux. https://gitnux.org/market-access-pharmaceutical-industry-statistics.
Sources & references
99 sources cited across this report
pmc.ncbi.nlm.nih.gov
- bourne-partners.com
ppd.com
ispe.org
pmlive.com
- techresearchinfo.com
test.benchling.com
insights.indegene.com
deloitte.com
pharmamanufacturing.com
monitor-industrial-ecosystems.ec.europa.eu
miebach.com
assets.kpmg.com
- f.hubspotusercontent00.net
veeva.com
capgemini.com
pistoiaalliance.org
iqvia.com
aspe.hhs.gov
- herbstkinsky.at
- hirc.com
- 20107649.fs1.hubspotusercontent-na1.net
- startadialogue.co.uk
naceweb.org
- jthelander.com
- innovatebio.org
- biobuzz.io
massbio.org
- remapconsulting.com
cultureamp.com
- amneal.com
- advance-hsg-report.ch
- investors.nxera.life
zs.com
axios.com
pharmavoice.com
web.phil.us
networksolutions.phreesia.com
media.bain.com
epocrates.com
- contentrevops.com
health-union.com
fiercepharma.com
bia.com
emarketer.com
- mboothhealth.com
- worldcomgroup.com
sermo.com
jamanetwork.com
- brand-news.it
mckinsey.com
efpia.eu
connect.aizon.ai
fda.gov
oecd.org
richmondfed.org
glginsights.com
cms.gov
medpac.gov
sec.gov
merck.com
tandfonline.com
ispor.org
cdn.cytivalifesciences.com
astrazeneca.com
mygreenlab.org
vertassets.blob.core.windows.net
novartis.com
- accesstomedicinefoundation.org
cdn.pfizer.com
- btlaw.com
- lifesciencesny.org
middlemarketcenter.org
acrohealth.org
fortinet.com
cpl.thalesgroup.com
- openpharma.blog
kiteworks.com
etla.fi
- insights.economistenterprise.com
- sebi.gov.in
grandviewresearch.com
pmarketresearch.com
klick.com
eversana.com
openhealthgroup.com
syneoshealth.com
lumanity.com
trinitylifesciences.com
certara.com
advi.com
precisionaq.com
ama-assn.org
Social media in the market access pharmaceutical industry